ProfileGDS5678 / 1444217_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 70% 68% 67% 69% 71% 70% 70% 70% 70% 71% 70% 70% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3487270
GSM967853U87-EV human glioblastoma xenograft - Control 24.3433470
GSM967854U87-EV human glioblastoma xenograft - Control 34.1967968
GSM967855U87-EV human glioblastoma xenograft - Control 44.1517967
GSM967856U87-EV human glioblastoma xenograft - Control 54.2885469
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3837271
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3847970
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3265670
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3234170
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3315570
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4894271
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3260370
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3369170
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3325770